Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 31, Pages 10769
Publisher
Baishideng Publishing Group Inc.
Online
2014-08-27
DOI
10.3748/wjg.v20.i31.10769
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- O-0003 * P-ERK, P-AKT AND P53 AS TISSUE BIOMARKERS IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED PANCREATIC CANCER: A TRANSLATIONAL SUBGROUP ANALYSIS FROM AIO-PK0104
- (2013) S. Boeck et al. ANNALS OF ONCOLOGY
- Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
- (2013) Minoru Oshima et al. ANNALS OF SURGERY
- Failure Patterns in Resected Pancreas Adenocarcinoma
- (2013) Jordan M. Winter et al. ANNALS OF SURGERY
- Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
- (2013) Lars Petter Jordheim et al. Biomarkers in Medicine
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
- (2013) A. B. Nixon et al. CLINICAL CANCER RESEARCH
- SPARC independent drug delivery and antitumour effects ofnab-paclitaxel in genetically engineered mice
- (2013) Albrecht Neesse et al. GUT
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
- (2013) Stefan Boeck et al. JOURNAL OF GASTROENTEROLOGY
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival
- (2013) Sang Hyun Shin et al. PANCREAS
- Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
- (2012) J. B. Bachet et al. ANNALS OF ONCOLOGY
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
- (2012) S Boeck et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma
- (2012) Hao Xie et al. CANCER
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- Pathology and Molecular Genetics of Pancreatic Neoplasms
- (2012) Laura D. Wood et al. CANCER JOURNAL
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- (2012) Takeshi Ogura et al. JOURNAL OF GASTROENTEROLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Overexpression of p53 protein in human tumors
- (2012) Keiji Inoue et al. Medical Molecular Morphology
- New biomarkers and targets in pancreatic cancer and their application to treatment
- (2012) Eithne Costello et al. Nature Reviews Gastroenterology & Hepatology
- Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
- (2012) Winnie S. Liang et al. PLoS One
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
- (2011) Soichiro Morinaga et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma
- (2011) Florian Gebauer et al. JOURNAL OF SURGICAL ONCOLOGY
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer
- (2011) Melissa Oliveira-Cunha et al. PANCREAS
- Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
- (2010) Gilda da Cunha Santos et al. CANCER
- Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
- (2010) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
- (2009) R Maréchal et al. BRITISH JOURNAL OF CANCER
- Targeting EGFR resistance networks in head and neck cancer
- (2009) Vladimir Ratushny et al. CELLULAR SIGNALLING
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of pancreatic cancer: an overview
- (2009) Sara Raimondi et al. Nature Reviews Gastroenterology & Hepatology
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search